Published in Schizophr Res on February 06, 2008
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 5.46
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
Metabolic syndrome in people with schizophrenia: a review. World Psychiatry (2009) 1.96
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry (2009) 1.70
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology (2010) 1.67
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry (2012) 1.48
Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. Schizophr Bull (2009) 1.40
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry (2010) 1.39
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Management of antipsychotic-related weight gain. Expert Rev Neurother (2010) 1.07
Using Non-experimental Data to Estimate Treatment Effects. Psychiatr Ann (2009) 1.01
A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One (2011) 0.99
Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med (2011) 0.98
Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry (2010) 0.97
Alternative methods for testing treatment effects on the basis of multiple outcomes: simulation and case study. Stat Med (2011) 0.93
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry (2009) 0.93
Metabolic syndrome in schizophrenia. Indian J Psychol Med (2013) 0.92
Anthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural population. J Neurosci Rural Pract (2012) 0.92
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci (2010) 0.91
How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatr Serv (2013) 0.90
Care provided by general practitioners to patients with psychotic disorders: a cohort study. BMC Fam Pract (2010) 0.88
Addressing cardiometabolic risk during treatment with antipsychotic medications. Curr Opin Psychiatry (2008) 0.88
The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol (2013) 0.87
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry (2009) 0.87
A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients. Psychopharmacology (Berl) (2013) 0.87
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci (2012) 0.86
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull (2009) 0.86
Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. Am Health Drug Benefits (2011) 0.86
The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl) (2015) 0.81
Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics. Ther Adv Psychopharmacol (2015) 0.81
APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia. PLoS One (2014) 0.80
Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr Res (2011) 0.80
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res (2008) 0.80
The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci (2010) 0.80
Prevalence of metabolic syndrome among patients with schizophrenia in Palestine. BMC Psychiatry (2012) 0.80
Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud (2013) 0.80
Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders. Transl Psychiatry (2013) 0.79
Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers. Br J Clin Pharmacol (2012) 0.78
Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus. Schizophr Bull (2015) 0.78
A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder. Ther Drug Monit (2013) 0.77
A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat (2013) 0.77
Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig (2015) 0.76
Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2016) 0.76
Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat (2015) 0.76
Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia. Neuropsychiatr Dis Treat (2013) 0.76
Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record. Prim Care Companion CNS Disord (2016) 0.75
A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia. Ther Adv Psychopharmacol (2012) 0.75
Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. Psychiatry Investig (2016) 0.75
Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study. Neuropsychiatr Dis Treat (2017) 0.75
Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann Gen Psychiatry (2017) 0.75
Patterns of Antipsychotic Prescribing by Physicians to Young Children. Psychiatr Serv (2016) 0.75
Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics (2014) 0.75
An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. Int J Endocrinol (2015) 0.75
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatr Dis Treat (2017) 0.75
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67
Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med (2006) 18.51
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA (2001) 8.56
A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry (2007) 7.49
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 5.84
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med (2003) 5.11
Diagnosis and classification of diabetes mellitus. Diabetes Care (2007) 4.78
Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med (2005) 4.76
The metabolic syndrome: requiescat in pace. Clin Chem (2005) 4.50
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation (1998) 3.42
Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry (2004) 3.36
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis (2004) 2.56
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry (2006) 2.31
The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. Int J Obes Relat Metab Disord (2002) 2.08
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res (2006) 1.88
The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res (2004) 1.85
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res (2006) 1.64
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry (2005) 1.61
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology (2006) 1.43
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry (2002) 1.38
Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol (2007) 1.38
Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry (2004) 1.37
A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry (2005) 1.34
Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA (2000) 1.29
Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia (2005) 1.22
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl (2004) 1.08
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology (2007) 1.08
High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol (2006) 1.04
Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry (2007) 0.94
An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: the Hoorn study. Am J Epidemiol (2005) 0.92
Insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab Res Rev (2001) 0.89
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res (2008) 5.99
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res (2011) 5.39
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res (2009) 3.68
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Systematic review: the value of the periodic health evaluation. Ann Intern Med (2007) 3.62
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Superseding psychiatric advance directives: ethical and legal considerations. J Am Acad Psychiatry Law (2006) 2.68
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res (2008) 2.67
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry (2002) 2.57
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry (2006) 2.49
Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res (2010) 2.47
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry (2005) 2.35